Glaukos Corp (GKOS)

Mar 11, 2025, 7:00 AM EDT - 22 days ago

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

Feb 24, 2025, 9:12 AM EST - 5 weeks ago

FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery

Feb 24, 2025, 7:00 AM EST - 5 weeks ago

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

Feb 21, 2025, 10:27 AM EST - 5 weeks ago

Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition

Feb 21, 2025, 4:29 AM EST - 5 weeks ago

Glaukos Corporation (GKOS) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 4:05 PM EST - 5 weeks ago

Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

Jan 23, 2025, 7:00 AM EST - 2 months ago

Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20

Jan 14, 2025, 4:05 PM EST - 2 months ago

Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform

Dec 31, 2024, 8:59 AM EST - 3 months ago

Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday

Dec 23, 2024, 7:00 AM EST - 3 months ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

Dec 21, 2024, 7:04 AM EST - 3 months ago

Glaukos: Still Bullish, But Embedded Expectations Are Now High

Dec 17, 2024, 7:00 AM EST - 3 months ago

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Dec 2, 2024, 2:29 PM EST - 4 months ago

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

ISRG NVRO SYK

Nov 8, 2024, 7:00 AM EST - 5 months ago

Glaukos Announces Participation in Upcoming Investor Conferences

Nov 5, 2024, 12:21 PM EST - 5 months ago

Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds

Nov 4, 2024, 11:03 PM EST - 5 months ago

Glaukos Corporation (GKOS) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 4:05 PM EST - 5 months ago

Glaukos Announces Third Quarter 2024 Financial Results

Oct 16, 2024, 4:05 PM EDT - 6 months ago

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety

Oct 14, 2024, 7:00 AM EDT - 6 months ago

Glaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual Meeting

Oct 9, 2024, 7:00 AM EDT - 6 months ago

Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4

Sep 23, 2024, 1:30 AM EDT - 6 months ago

Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement

Jul 31, 2024, 8:57 PM EDT - 8 months ago

Glaukos Corporation (GKOS) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 4:05 PM EDT - 8 months ago

Glaukos Announces Second Quarter 2024 Financial Results

Jul 10, 2024, 9:05 AM EDT - 9 months ago

This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

V HELE LZ SPOT

Jul 10, 2024, 7:00 AM EDT - 9 months ago

Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31

Jun 14, 2024, 7:00 AM EDT - 10 months ago

Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock

May 1, 2024, 8:42 PM EDT - 1 year ago

Glaukos Corporation (GKOS) Q1 2024 Earnings Call Transcript

May 1, 2024, 4:05 PM EDT - 1 year ago

Glaukos Announces First Quarter 2024 Financial Results

Apr 16, 2024, 4:05 PM EDT - 1 year ago

Glaukos Announces the Release of its 2023 Sustainability Report

Apr 10, 2024, 7:00 AM EDT - 1 year ago

Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1

Apr 3, 2024, 7:00 AM EDT - 1 year ago

Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

Feb 21, 2024, 11:13 PM EST - 1 year ago

Glaukos Corporation (GKOS) Q4 2023 Earnings Call Transcript

Feb 21, 2024, 4:05 PM EST - 1 year ago

Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results

Jan 31, 2024, 7:00 AM EST - 1 year ago

Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21

Jan 9, 2024, 7:00 AM EST - 1 year ago

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance

Jan 5, 2024, 7:31 AM EST - 1 year ago

Alger's Amy Zhang gives her top small-cap stock picks for 2024

NTRA

Dec 14, 2023, 7:00 AM EST - 1 year ago

Glaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant)

Nov 7, 2023, 7:00 AM EST - 1 year ago

Glaukos Announces Participation in Stifel Healthcare Conference

Nov 1, 2023, 11:04 PM EDT - 1 year ago

Glaukos Corporation (GKOS) Q3 2023 Earnings Call Transcript

Nov 1, 2023, 4:05 PM EDT - 1 year ago

Glaukos Announces Third Quarter 2023 Financial Results

Oct 31, 2023, 7:00 AM EDT - 1 year ago

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Academy of Ophthalmology Annual Meeting

Oct 11, 2023, 7:00 AM EDT - 1 year ago

Glaukos to Release Third Quarter 2023 Financial Results after Market Close on November 1, 2023

Aug 23, 2023, 7:00 AM EDT - 1 year ago

Glaukos Announces Participation in Wells Fargo Healthcare Conference

Aug 2, 2023, 9:30 PM EDT - 1 year ago

Glaukos Corporation (GKOS) Q2 2023 Earnings Call Transcript

Aug 2, 2023, 4:05 PM EDT - 1 year ago

Glaukos Announces Second Quarter 2023 Financial Results

Jul 17, 2023, 7:00 AM EDT - 1 year ago

Glaukos Enters into a Collaboration and Marketing Agreement with Radius XR, Inc.

Jul 12, 2023, 7:00 AM EDT - 1 year ago

Glaukos to Release Second Quarter 2023 Financial Results after Market Close on August 2, 2023

Jun 16, 2023, 6:13 AM EDT - 1 year ago

Glaukos: Revising To Buy On These 3 Catalytic Factors

Jun 5, 2023, 7:00 AM EDT - 1 year ago

Glaukos Achieves Pipeline Milestone with Enrollment Completion in Phase 3 Confirmatory Trial for Epioxa (Epi-on)